ArticleBiomacromolecules2025
Designed Fibril-Forming Mini-Collagens Engineered to Exhibit up to Two Orders of Magnitude Differences in Rates of Matrix Metalloproteinase I Susceptibility.
Article in Biomacromolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The susceptibility to matrix metalloproteinases (MMPs) directly affects the functions and applications of collagen biomaterials. In this work, we demonstrated that this property can be manipulated in collagen-mimetic biomaterials created using designed peptides. We developed three fibril-forming mini-recombinant collagens (MRCs) using bacterial expression and designed genes that model a 108-residue section of human type III collagen surrounding the MMP-1 recognition site. Notably, the MRCs can form a native-like fibrillar structure representing the natural substrate of MMP-1. By altering the number of digestion sites or mutating the residues at the canonical scissile bond of MMP-1, the sensitivity to proteolysis of the MRCs varied by two orders of magnitude despite having homologous amino acid sequences and a similar fibrillar structure, and regardless of whether the peptides were in the triple helix conformation or as fibrils. These MRCs can be a versatile collagen alternative for regenerative medicine offering a regulated turnover rate catering to specific applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.